Early Use of Methylene Blue in Vasoplegic Syndrome: A 10-Year Propensity Score-Matched Cohort Study.

Othmar KoflerMaximilian SimbeckRoland TomasiLudwig Christian HinskeLaura Valentina KlotzFlorian Uhle Frank Born Maximilian A PichlmaierChristian HaglMarkus Alexander WeigandBernhard ZwißlerVera von Dossow

Published in: Journal of clinical medicine (2022)

Our results indicate the additive effects of MB use during VS compared to standard vasopressor therapy only. Early MB administration for VS may significantly improve the patients' hemodynamics with minor side effects.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
stem cells
case report
patient reported outcomes